OptimizeRx (OPRX) CBO Andrew D'Silva Receives RSU Award

What Happened

• Andrew J. D'Silva, Chief Business Officer of OptimizeRx (OPRX), received a grant of 57,600 restricted stock units (RSUs) on August 20, 2026. The reported acquisition price is $0.00 (an award/compensation grant), so no cash was paid. The filing reports the grant but does not list shares owned after the grant.

Key Details

• Transaction date: 2026-08-20 (Form filed 2026-08-24).
• Transaction type/code: Award/Grant (A).
• Shares involved: 57,600 RSUs; reported acquisition price $0.00; total reported cash consideration $0.
• Vesting: Footnote states RSUs vest in three equal annual installments beginning August 20, 2027 (first anniversary of grant).
• Shares owned after transaction: not disclosed in the Form 4.
• Filing timeliness: Filed Aug 24, 2026 — appears to be within the typical two business-day reporting window for Section 16 insiders.

Context

• RSUs are a contingent right to receive shares upon vesting; they are compensation rather than an open-market purchase or sale and do not result in immediate share sales. Upon vesting, RSUs typically convert to shares (and may be subject to tax withholding), which can dilute existing shareholders over time. This filing documents a compensation award rather than an outright market transaction.